Under ‘Age < 50 & LINC00673 expression’: Low 24, High 14, P value = 0.446 should be corrected to Low 17, High 21, P value = 0.370.
Under ‘Tumor size ≤2cm & LINC00673 expression’: Low 20, High 11, P value = 0.024 should be corrected to Low 21, High 10, P value = 0.011.
Under ‘Negative PR expression’: 45 should be corrected to 48.
Anzeige
As a result, a sentence in the section ‘LINC00673 is upregulated in breast cancer tissues and cell lines’ should be changed as well.
The sentence currently reads:
LINC00673 expression was positively correlated with tumor size (P = 0.024), and Ki67 status (P = 0.019).
The sentence should read:
LINC00673 expression was positively correlated with tumor size (P = 0.011), and Ki67 status (P = 0.019).
2.
In the ‘Methods, Statistical analysis’ section, the term ‘Spearman’s’ had been incorrectly used.
The sentence currently reads:
The correlation between LINC00673 and MARK4 expression was analyzed using Spearman’s correlation test.
The sentence should read:
Anzeige
The correlation between LINC00673 and MARK4 expression was analyzed using Pearson’s correlation test.
3.
An error was identified in the figure legend of Fig. 4a.
The sentence currently reads:
The red color indicates genes that were upregulated compared with the control cells, and the blue color indicates genes that were downregulated compared with the control cells.
The sentence should read:
Anzeige
The red to blue color gradient indicates high to low expression levels, respectively.
4.
In the section ‘LINC00673 regulates MARK4 expression by competing for miR-515-5p’, the number ‘18’ needs to be corrected to ‘17’ in the sentence ‘Among these miRNAs, we verified that the expression of 18 miRNAs were significantly increased by the knockdown of LINC00673 (Fig. 5b and c)’.
The correct sentence should read:
Among these miRNAs, we verified that the expression of 17 miRNAs were significantly increased by the knockdown of LINC00673 (Fig. 5b and c).
5.
An error was identified in the Fig. 6e, which should have indicated LINC00673 expression in MDA-MB-231 cells after transfection with Lv-YY1, was mistakenly displayed as a duplicate of Fig. 6d, due to the authors’ carelessness during the layout of figure.
6.
An error was identified in Fig. 6g. The phosphorylated YAP/TAZ in cytoplasm should have been non-phosphorylated YAP/TAZ. In addition, to better understand the mechanism of the regulatory network and function of LINC00673, the authors added up and down arrows in Fig. 6g. In the figure legend of Fig. 6g, the second sentence contains an error. The authors had incorrectly used the term ‘induced’, and it should be changed to ‘reduced’. As a result, the second sentence in the figure legend of Fig. 6g ‘LINC00673 promoted proliferation, induced apoptosis in breast cancer cells which could be enhanced by YY1 and acted as a ceRNA for miR-515-5p to regulate MARK4 and inactivate the Hippo signaling pathway.’ should be changed to ‘LINC00673 promoted proliferation, reduced apoptosis in breast cancer cells which could be enhanced by YY1 and acted as a ceRNA for miR-515-5p to regulate MARK4 and inactivate the Hippo signaling pathway.’
7.
Figure 5 is not clear in the article, and should be replaced with an updated one with high resolution.
8.
Additional File 1 Figure S1 and Additional File 2 Figure S2 were mistakenly displayed as Fig. 1 and Fig. 2.
The updated figures and tables are shown below:
Table 1
Correlation between LINC00673 expression and the clinicopathological features of breast cancer
Characteristics
No.
(n = 80)
LINC00673 expression
P-value
Low (n = 40)
High (n = 40)
Age
0.370
< 50
38
17
21
≥ 50
42
23
19
Tumor size
0.011*
≤ 2 cm
31
21
10
> 2 cm
49
19
30
LNM
0.097
Negative
27
17
10
Positive
53
23
30
TNM stage
0.089
I-II
74
39
35
III-IV
6
1
5
ER expression
0.485
Negative
29
16
13
Positive
51
24
27
PR expression
Negative
48
23
25
0.648
Positive
32
17
15
Her-2 expression
0.368
Negative
44
24
20
Positive
36
16
20
Ki67 expression
0.019*
≤ 14%
28
19
9
> 14%
52
21
31
LNM lymph node metastasis, *P < 0.05
Fig. 5
LINC00673 regulates MARK4 expression by competing for miR-515-5p. a The subcellular distribution of LINC00673 in MDA-MB-231 and MDA-MB-453 cells. GAPDH was used as the cytoplasmic control, and U1 served as the nuclear control. b-c The relative expression of miRNAs was determined by qRT-PCR after the knockdown of LINC00673. d The expression of miR-515-5p was measured after the knockdown of LINC00673 by using qRT-PCR in MDA-MB-231 and MDA-MB-453 cells. e Expression of LINC00673 in miR-515-5p mimics or inhibitor transfected MDA-MB-231 and MDA-MB-453 cells, as determined by qRT-PCR. f-g Elevation and depression of miR-515-5p was inversely related to MARK4 expression, as determined by qRT-PCR and western blotting. h Luciferase reporter assays were used to verify the targeted binding between LINC00673 or MARK4 3’untranslated region (UTR) and miR-515-5p. i The expression of MARK4, YAP and TAZ in MDA-MB-231 and MDA-MB-453 cells transfected with LINC00673 siRNA or cotransfected with a LINC00673 siRNA and an miR-515-5p inhibitor, as determined by qRT-PCR. j Western blot analysis of MARK4, p-YAP, YAP and TAZ expression levels in MDA-MB-231 and MDA-MB-453 cells transfected with LINC00673 siRNA or cotransfected with LINC00673 siRNA and miR-515-5p inhibitor. k-l CCK-8 assays were used to examine the cell proliferation ability after LINC00673 knockdown in MDA-MB-231 and MDA-MB-453 cells transfected with miR-515-5p inhibitors and LINC00673-overexpressing cells transfected with miR-515-5p mimics. The data are presented as the mean ± the SD of three independent experiments. *P < 0.05, ** P < 0.01, and *** P < 0.001
Fig. 6
YY1 activates LINC00673 expression in breast cancer cells. a YY1 binding motif and the prediction of YY1 binding sites within the promoter region of LINC00673 provided by the JASPAR database. b The knockdown efficiency of YY1 in MDA-MB-231 cells was determined by qRT-PCR and western blotting. c qRT-PCR analysis of LINC00673 expression in MDA-MB-231 cells after transfection with YY1 siRNA and the negative control. d The overexpression efficiency of YY1 in MDA-MB-231 cells was determined by qRT-PCR and western blot analysis. e qRT-PCR analysis of LINC00673 expression in MDA-MB-231 cells after transfection with Lv-YY1 and the negative control. f qRT-PCR of the ChIP products validating the binding capacity of YY1 to the LINC00673 promoter. g The mechanism of the regulatory network and function of LINC00673. LINC00673 promoted proliferation, reduced apoptosis in breast cancer cells which could be enhanced by YY1 and acted as a ceRNA for miR-515-5p to regulate MARK and inactivate the Hippo signaling pathway. The data are presented as the mean ± the SD of three independent experiments. ** P < 0.01 and *** P < 0.001
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
